Design Therapeutics, Inc. reports that Point72-related filers beneficially own 3,197,764 shares of common stock, equal to 5.1% of the class, as of the close of business on June 8, 2026. The disclosure is made on a Schedule 13G and identifies shared voting and dispositive power among Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen.
Positive
None.
Negative
None.
Insights
Point72 reports a passive >5% holding disclosed via Schedule 13G.
The filing lists 3,197,764 shares and a 5.1% ownership stake as of June 8, 2026, with shared voting and dispositive power reported. The statement is filed jointly by Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen under Rule 13d-1(k).
Because this is a 13G filing, it characterizes the position as passive in this disclosure; subsequent amendments or a switch to an active intent filing would change the regulatory profile and require further filings.
Ownership is held on behalf of Point72 Associates and reported by affiliated entities.
The cover rows show shared voting power 3,197,764 and shared dispositive power 3,197,764, with Point72 Associates identified as the entity with the right to receive proceeds. The joint filer agreement is attached as Exhibit 99.1.
Watch for future amendments if voting intent or percent ownership crosses regulatory thresholds; timing of any change is not provided here.
Key Figures
Beneficial ownership:3,197,764 sharesPercent of class:5.1%Shared voting power:3,197,764 shares+1 more
4 metrics
Beneficial ownership3,197,764 sharesas of June 8, 2026
"statement is filed on a Schedule 13G and identifies beneficial ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficially ownedfinancial
"Amount beneficially owned: The information required by Item 4(a)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive powergovernance
"Shared Dispositive Power 3,197,764.00"
Joint Filing Agreementregulatory
"entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 99.1"
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
What stake did Point72 report in Design Therapeutics (DSGN)?
Point72-related filers reported beneficial ownership of 3,197,764 shares, equal to 5.1% of the common stock as of June 8, 2026. The position is reported on a Schedule 13G by Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen.
Does the Schedule 13G indicate Point72 has voting control over DSGN shares?
The filing shows shared voting power of 3,197,764 shares and shared dispositive power for the same amount. It states Point72 Asset Management maintains investment and voting power for shares held by Point72 Associates as of June 8, 2026.
Who holds the economic interest in the reported DSGN shares?
The statement explains that the shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, and that Point72 Associates has the right to receive dividends or sale proceeds for the >5% interest reported as of June 8, 2026.
What document formalizes the joint filing by Point72 entities for DSGN?
The filers state they entered into a Joint Filing Agreement, which is filed as Exhibit 99.1. The agreement is referenced in the Schedule 13G and governs the joint submission under Rule 13d-1(k).
Does this Schedule 13G signal active intent to influence Design Therapeutics?
This filing is a Schedule 13G disclosure, which typically indicates a passive reporting status under Rule 13d-1. The statement does not assert active solicitation or change in intent; any change would require a different filing by the reporting persons.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Design Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
25056L103
(CUSIP Number)
06/08/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
25056L103
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,197,764.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,197,764.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,197,764.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
25056L103
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,197,764.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,197,764.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,197,764.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
25056L103
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,197,764.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,197,764.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,197,764.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Design Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Design Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited and Point72 Asia (Singapore) Pte. Ltd. are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
25056L103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 8, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
(b)
Percent of class:
5.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 8, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 8, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 8, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on June 8, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
